MK-3475-U01
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer
Recruiting
Trial Purpose
This study is referred to as the “umbrella master protocol” for pembrolizumab (MK-3475) in the treatment of non-small cell lung cancer (NSCLC). This pembrolizumab NSCLC umbrella master protocol uses a platform design and consists of this master screening study and additional substudies. Each substudy will enroll a different population of NSCLC participants.
View full trial information on Clinicaltrials.gov
 |
National Trial Reference Number | NCT04165798 |
 |
MSD Protocol ID |
MK-3475-U01 |
 |
Conditions |
Carcinoma, Non-Small-Cell Lung |
 |
Age Range |
18+ |
 |
Sex | ALL |
 |
Trial Phase | |
 |
Start Date End Date |
2019-12-19 2032-02-13 |
Study Details
Patient Participation
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial.
Conditions
Carcinoma, Non-Small-Cell Lung
Trial Locations
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.
What can you do next?
If you think this clinical trial might be a good fir and you are interested in taking part, take the next step to see if you are eligible.
Discuss with your doctor or care team
Print this page with details about the trial or email it to your doctor to discuss the clinical trial during your next visit.
To learn more, call 1-888-577-8839